185 related articles for article (PubMed ID: 25293578)
1. Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes.
Dallow J; Otterson LG; Huband MD; Krause KM; Nichols WW
Int J Antimicrob Agents; 2014 Dec; 44(6):552-6. PubMed ID: 25293578
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients.
Flamm RK; Nichols WW; Sader HS; Farrell DJ; Jones RN
Int J Antimicrob Agents; 2016 Mar; 47(3):235-42. PubMed ID: 26920105
[TBL] [Abstract][Full Text] [Related]
3. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
4. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
6. Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying
Castanheira M; Mendes RE; Sader HS
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031200
[No Abstract] [Full Text] [Related]
7. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012).
Flamm RK; Farrell DJ; Sader HS; Jones RN
J Antimicrob Chemother; 2014 Jun; 69(6):1589-98. PubMed ID: 24562613
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.
Vasoo S; Cunningham SA; Cole NC; Kohner PC; Menon SR; Krause KM; Harris KA; De PP; Koh TH; Patel R
Antimicrob Agents Chemother; 2015 Dec; 59(12):7842-6. PubMed ID: 26392487
[TBL] [Abstract][Full Text] [Related]
10. Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011).
Flamm RK; Sader HS; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2014 Nov; 80(3):233-8. PubMed ID: 25128477
[TBL] [Abstract][Full Text] [Related]
11. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
Nicolau DP
Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
[TBL] [Abstract][Full Text] [Related]
13. Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014.
Sader HS; Castanheira M; Flamm RK; Huband MD; Jones RN
Surg Infect (Larchmt); 2016 Aug; 17(4):473-8. PubMed ID: 27104633
[TBL] [Abstract][Full Text] [Related]
14. Distinctive Binding of Avibactam to Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria.
Asli A; Brouillette E; Krause KM; Nichols WW; Malouin F
Antimicrob Agents Chemother; 2016 Feb; 60(2):752-6. PubMed ID: 26574008
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
Falcone M; Paterson D
J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599
[TBL] [Abstract][Full Text] [Related]
16. The β-Lactams Strike Back: Ceftazidime-Avibactam.
Zasowski EJ; Rybak JM; Rybak MJ
Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
[TBL] [Abstract][Full Text] [Related]
17. Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value.
Flamm RK; Stone GG; Sader HS; Jones RN; Nichols WW
J Chemother; 2014 Dec; 26(6):333-8. PubMed ID: 24125508
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens.
Stone GG; Bradford PA; Newell P; Wardman A
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872067
[TBL] [Abstract][Full Text] [Related]
19. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
Liscio JL; Mahoney MV; Hirsch EB
Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
[TBL] [Abstract][Full Text] [Related]
20. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.
Papp-Wallace KM; Becka SA; Zeiser ET; Ohuchi N; Mojica MF; Gatta JA; Falleni M; Tosi D; Borghi E; Winkler ML; Wilson BM; LiPuma JJ; Nukaga M; Bonomo RA
ACS Infect Dis; 2017 Jul; 3(7):502-511. PubMed ID: 28264560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
